Dr. Dmitri V. Gelfand, MD

Dr. Gelfand practices at Sutter Valley Medical Foundation in Roseville, California.

Dr. Gelfand's NPI, 1205093176, was assigned on May 19, 2008. Dr. Gelfand graduated from UC Irvine School of Medicine in 2001. Dr. Gelfand holds California license A80877.

Dr. Gelfand's primary practice is Sutter Valley Medical Foundation, at 3 Medical Plz, Roseville, CA 95661 in Placer County. The practice phone is (800) 470-0071.

Dr. Gelfand's primary practice is Sutter Valley Medical Foundation in Roseville, California. Dr. Gelfand is also affiliated with Sutter Roseville Medical Center. The medical group on file is SGMF Radiology. Dmand AI also links Dr. Gelfand to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gelfand practices, 4 sites in all. Vendor and product names are available with a free account.

Vascular surgery is Dr. Gelfand's primary specialty in the NPI Registry, under taxonomy code 2086S0129X. Dr. Gelfand is board certified in surgery by the American Board of Surgery. Dmand AI has Dr. Gelfand's licenses on file in 2 states: California and New York.

Dmand AI lists aortic atherosclerois, arterial blot clot /embolism, blood vessel access for dialysis, carotid revascularization, chronic skin ulcer, deep vein thrombosis (DVT), heart device and aorta surgery and leg revascularization among the conditions Dr. Gelfand treats.

CMS data shows 2,222 Medicare services from Dr. Gelfand across 26 procedure codes in 2024, for 799 Medicare patients. Medicare paid $249,028 for them.

CMS counts 799 Medicare patients who saw Dr. Gelfand in 2024. The largest group is 75 to 84, with 343 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 19% are also on Medicaid. Their average risk score is 2.23, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gelfand's median patient age at 76, with 44% women.

In 2024, Dr. Gelfand wrote 802 Medicare Part D claims for 210 patients. 93% of them were for generic drugs. CMS names the drug for 769 of them, across 10 drugs with 11 or more claims each, at $39,522 in total drug cost. In 2023, CMS named 652 claims across 7 drugs.

Dr. Gelfand accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gelfand as offering telehealth. CMS counts 14 procedures of leg revascularization (restoring blood flow) by Dr. Gelfand, more than 70% of the clinicians it reports for that procedure.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 16 papers to Dr. Gelfand, published from 2006 to 2023. The most frequent topics are Laparoscopy, Gastric Bypass and General Surgery. Dr. Gelfand has published most often in Arch Surg. Dr. Gelfand's most frequent co-authors are Samuel Eric Wilson, MD, Ninh T. Nguyen, MD and Trung D. Bui, MD.

Dmand AI links Dr. Gelfand to 2 clinical trials. Conditions studied include Aortic Aneurysm, Abdominal and Aortic Aneurysm.

CMS Open Payments shows 97 general payments to Dr. Gelfand from 18 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 96% of the total. W. L. Gore & Associates, Inc. paid the most, $1,907.

Dmand AI lists 2 awards for Dr. Gelfand, most recently CMS Stage 1 EHR in 2012.

Dr. Gelfand graduated from UC Irvine School of Medicine in 2001. Dr. Gelfand is a member of ACS and SVS.

Dr. Gelfand is in network with 12 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.